Antitumor activity mouse B16-BL6 cells implanted in C57BL/6 mouse assessed tumor growth inhibition at 15 mg/kg, ip dosed every other day for 18 days relative to control
Antitumor activity mouse B16-BL6 cells implanted in C57BL/6 mouse assessed tumor growth inhibition at 7.5 mg/kg, ip dosed every other day for 18 days relative to control
Antitumor activity mouse B16-BL6 cells implanted in C57BL/6 mouse assessed tumor growth inhibition at 30 mg/kg, ip dosed every other day for 18 days relative to control
Antitumour activity against mouse B16-BL6 cells allografted in C57BL/6 mouse assessed as reduction in tumor mass at 7.5 mg/kg, ip administrated every other day relative to control
Antitumour activity against mouse B16-BL6 cells allografted in C57BL/6 mouse assessed as reduction in tumor mass at 3 mg/kg, ip administrated every other day relative to control
Antitumour activity against mouse B16-BL6 cells allografted in C57BL/6 mouse assessed as reduction in tumor mass at 30 mg/kg, ip administrated every other day relative to control
Antitumor activity against mouse B16-BL6 cells implanted in C57BL/6jNpa mouse assessed as primary tumor growth inhibition at 100 mg/kg, po qd administered started on day 7 post implantation measured after 21 days relative to control
Antitumor activity against mouse B16-BL6 cells implanted in C57BL/6jNpa mouse assessed as metastatic tumor growth inhibition at 100 mg/kg, po qd administered started on day 7 post implantation measured after 21 days relative to control
Antitumor activity against mouse B16-BL6 cells implanted in C57BL/6jNpa mouse assessed as reduction in TIE-2 levels metastases lysate of at 3 mg/kg, po qd administered started on day 7 post implantation measured after 21 days by ELISA analysis
Antitumor activity against mouse B16-BL6 cells implanted in C57BL/6jNpa mouse assessed as metastatic tumor growth inhibition at 3 mg/kg, po qd administered started on day 7 post implantation measured after 21 days relative to control